Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells by Xiaoqin Luo et al.
Luo et al. Nutrition & Metabolism 2012, 9:34
http://www.nutritionandmetabolism.com/content/9/1/34RESEARCH Open AccessDocosahexaenoic acid ameliorates palmitate-
induced lipid accumulation and inflammation
through repressing NLRC4 inflammasome
activation in HepG2 cells
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Background: N-3 polyunsaturated fatty acids, such as docosahexaenoic acid (DHA; 22:6n-3), has clinical significance
in the prevention and reversal of nonalcoholic steatohepatitis (NASH). However, the precious mechanism underlying
remains unclear. The inflammasome, a multiprotein complex formed by NOD-like receptor (NLR) family members,
has been recently shown to be activated in NASH and promote the cleavage of the pro-inflammatory cytokines to
their maturation forms.
Methods: HepG2 cells were exposed to different dose of PA for 24 h with or without the preincubation of 50 μM
DHA for another 24 h and then lipid deposition was assessed with Oil red O staining and intracellular triglyceride
(TG) determination. Secretory levels of inflammatory cytokines and Caspase-1 activity were determined by ELISA
assays. Gene expression and protein levels were determined by quantitative RCR and western blotting, respectively.
Results: Palmitate (PA) dose-dependently increased lipid accumulation, TG content and induced the secretion of
interleukin-1β (IL-1β), IL-18, TNF-α and MCP-1 from HepG2 cells. Preincubation with DHA significantly alleviated
PA-induced lipid accumulation and inflammatory agents. DHA was also found to attenuate PA-induced NOD-like
receptor protein 4 (NLRC4) mRNA expression. Furthermore, PA induced caspase-1 activation in a dose-dependent
manner, resulting in exacerbating of procaspase-1 and pro-IL-1β processing. Knockdown of NLRC4 partially
abrogated PA-induced caspase-1 activation and IL-1β maturation and completely abolished these events in the
presence of DHA.
Conclusions: Our findings indicate DHA attenuates PA-induced lipid accumulation and inflammation through
suppressing NLRC4 inflammasome activation, caspase-1 activation and IL-1β cleavage.
Keywords: Docosahexaenoic acid, Inflammation, Lipid accumulation, Nonalcoholic steatohepatitis, NLRC4
inflammasome, PalmitateBackground
Non-alcoholic fatty liver disease (NAFLD) is a worldwide
common liver disease that has an increasing prevalence
not only in adults with metabolic syndrome but also in
obese children and adolescents [1-3]. Non-alcoholic stea-
tohepatitis (NASH) is one of pathologic stages of NAFLD* Correspondence: lingwh@mail.sysu.edu.cn
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reproduction in any medium, provided the orand the main histopathological changes are steatosis, in-
flammation and hepatocyte injury with or without fibrosis
[4]. Although the precise mechanisms need to be eluci-
dated, the two-hit hypothesis of NASH has been widely
accepted [5]. The 1st hit involves fat accumulation in the
liver as a result of excessive delivery of free fatty acids
(FFAs) from the adipose tissue, and imbalance of lipid syn-
thesis and export in hepatocyte. The consequent injures
such as oxidative stress and inflammation are regarded as
the 2nd hit culminating in fibrosis of liver.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inflammatory mediators in NASH, less is known about
how the inflammatory mediators are generated. Recent
studies implicated that the inflammasomes have emerged
as pivotal sensors of infection and stress in intracellular
compartments and appear to regulate the production of
the proinflammatory cytokines IL-1β and IL-18 [6,7]. It
has been demonstrated that one of the NOD-like recep-
tor (NLR) family members, NOD-like receptor protein 3
(NLRP3) inflammasome, was involved in caspase-1 acti-
vation and caspase-1-mediated IL-1β and IL-18 release
[8]. However, the role of another inflammasome NOD-
like receptor protein 4 (NLRC4) on the generation of
inflammatory mediators in NASH has not been elucidated.
Many studies have suggested that FFAs composition
and abnormal fatty acid metabolism have been impli-
cated in the pathogenesis of NASH [9-12]. Diets with a
high intake of fat, especially saturated fatty acids, may
promote the development of NASH [13,14]. Conversely,
polyunsaturated fatty acids (PUFAs), such as docosa-
hexaenoic acid (DHA), have been found to decrease
liver fat content in children with NAFLD and possess
anti-inflammatory effects [15,16]. It has been reported
that PA induced the activation of the NLRP3 inflamma-
some which then senses obesity-associated danger signals
and contributes to obesity-induced inflammation [17,18].
However, the effects of DHA on NLRC4 inflammasome in
PA-induced inflammatory responses remain unknown. In
the present study, our findings demonstrated that NLRC4
inflammasome is activated in PA-induced lipid accumula-
tion and inflammation; and that DHA alleviates these
events by suppressing the activity of caspase-1 and the




DHA (Sigma, St. Louis, MO) was dissolved in ethanol
(stock solution 100 mM). Stock solutions were kept at −20°
C before the experiments. PA (Sigma, St. Louis, MO) was
conjugated with FFA-free bovine serum albumin (BSA) at a
5:1 molar ratio before treatment as previously described
[19]. Solutions and reagents used for cell cultures were
from GIBCO Life Technologies Ltd. (Grand Island, NY,
USA). Antibodies used are from Cell Signaling Technology
Inc. (Danvers, MA, USA). All other reagents and kits were
purchased from Sigma Aldrich and Invitrogen (Carlsbad,
CA, USA) unless otherwise noted.
Cell culture and stimulation
HepG2 cells (ATCC, Manassas, VA, USA) were routinely
cultured with Dulbecco’s Modified Eagle’s Medium contain-
ing 10% fetal bovine serum. 2×104 cells were seeded into
24-well plates 24 h prior to treatments at approximately60% confluence. After the starvation for 24 h, cells were
exposed to different dose of PA for 24 h with or without
the preincubation of 50 μM DHA for another 24 h. BSA
and ethanol were used as controls. Cell viability after FFA
treatments was monitored by trypan blue exclusion. No
change in viability was observed with the concentrations
used in this study. To knock down NLRC4 expression,
HepG2 cells were transfected with 20 pmol NLRC4 siRNA,
a commercially available small interfering RNAs (siRNAs)
duplex components against this molecule (sc-60328A,
sc-60328B and sc-60328 C; Santa Cruz, CA, USA) or a
negative control siRNA (sc-37007; Santa Cruz, CA, USA),
a RNA duplex with no known sequence homology, in
a 24-well format using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer's instructions.
Observation of lipid accumulation
The lipid accumulation in HepG2 cells was evaluated by
Oil Red O staining and the measurement of triglyceride
(TG) content. Briefly, samples were fixed with 4% paraf-
ormaldehyde then stained with Oil Red O for 15 min.
Then, the samples were counterstained with hematoxylin
for 5 min. Results were examined by light microscopy.
Intracellular TG content was evaluated after lysis of the
cells with 1 × cell lysis buffer (1% Triton X-100, 150 mM
NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA,
0.2 mM phenylmethylsulfonylfluoride, 0.2 mM sodium
orthovanadate, and 0.5% NP-40) (Promega, Madison,
WI, USA). TG concentration was determined by the
EnzyChromTM triglyceride assay kit (Bioassay Systems)
according to the protocal provided by manufacturer and
normalized by protein content.
Measurement of inflammatory cytokines by ELISA assay
The cell culture media were centrifuged at 10,000 g for
10 min at 4°C and the supernatants were stored at −20°C
before analysis. Secretory levels of inflammatory cyto-
kines, including TNF-α, IL-1β, IL-18 and MCP-1 pro-
teins, in cell-free culture supernatants were determined
by Quantikine ELISA kit (R&D Systems Inc, Mineapolis,
USA). The color generated was determined by measuring
the OD value at 450 nm of spectrophotometric microtiter
plate reader (Molecular Devices Corp., Sunnyvale, CA,
USA). A standard curve was run on each assay plate using
recombinant proteins in serial dilutions. The limits of
sensitivity of the kits are 0.5, 7.0, 3.9 and 5.5 pg/mL for
TNF-α, IL-1β, IL-18 and MCP-1, respectively.
Real-time PCR assay of NLRC4 mRNA in HepG2 cells
Total RNA in cells was isolated using TRIzol reagent
and reversely transcribed to cDNA using Super Script II
Rnase H Reverse Transcriptase (Invitrogen, Carlsbad,
Calif ) according to the manufacturer’s instructions. The
cDNA samples were stored at −20°C for real-time PCR.
Figure 1 DHA suppresses PA-induced lipids accumulation in
HepG2 cells. (A) Representative Oil Red O staining of cells with
different treatments is shown. Cells were examined by light
microscopy at a magnification of 400×; (B) Intracellular TG content
was measured by an ELISA assay. TG concentration was normalized
by protein content. Data are shown as the mean± S.E.; n = 4.
*P< 0.05, **P< 0.01 compared with untreated cells; #P< 0.01 versus
0.4 mM PA-treated cells.
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software as the following: 5’-CCAGTCCCCTCACCATA-
GAAG-3’ (forward) 5’-ACCCAAGCTGTCAGTCAGACC-
3’ (reverse) for NLRC4; 5’-CCTGGCACC- CAGCACAAT-
3’ (forward) and 5’-GCCGATCCACACGGAGTACT-3’
(reverse) for β-actin. Real-time PCR was done with SYBR
Green PCR Master Mix (Invitrogen, Carlsbad, Calif ) using
a 7500 Real-Time PCR System (Applied Biosystems). Melt
curve analysis was included to assure a single PCR product
was formed. Values were corrected using human β-actin
gene. The relative NLRC4 mRNA levels were presented as
percentage of that in control cells.
Western blotting
Cellular protein was extracted with 1 × cell lysis buffer.
Protein concentration was determined using the BCATM
assay kit from Thermo Fisher Scientific Inc. (Huntsville,
AL) according to the user manual. Protein (40 μg) from
each sample was separated by 10-12% SDS-PAGE and
electrotransferred to polyvinyl denedifluoride (PVDF)
membranes. The membranes were blocked with 5% BSA
in TBS for 1 h at room temperature and incubated over-
night at 4°C using the following primary antibodies:
1:1000 rabbit anti β-actin, 1:500 NLRC4 (Santa Cruz,
CA, USA), 1:1000 caspase-1 and 1:500 IL-1β, followed by
1:2000 dilution of goat anti-rabbit horseradish peroxidase-
labeled antibody. The bands were visualized using the ECL
system, and the band density was determined by Image J
software (NIH, USA).
Caspase-1 activity assay
HepG2 cells were homogenized in 1 × cell lysis buffer
and caspase-1 activity was determined using colorimetric
assay based on the cleavage of the substrate Aacetyl-Tyr-
Val-Ala-Asp p-nitroanilide (Ac-YVAD-pNA) (R&D Sys-
tems, Minneapolis, MN, USA). 1 × 104 cells were seeded
into 96-well plates and treated in the same way as the
method mentioned above. Then, cell-free culture media
were analyzed with caspase-1 activity commercial kit
according to the protocols provided by the manufacturer.
Briefly, 90 μL standards, samples or control was added
to the appropriate microtiter wells, and then 10 μL Ac-
YVAD-pNA was pipetted into each well, and incubated
for 2 h at 37°C. and the absorbance of each well at
405 nm was recorded after calibrating the plate reader
against the chromogen blank. Cleavage of the substrate
by caspase-1 releases pNA that can subsequently be
quantified by the absorbance difference.
Statistical analyses
All of the experiments were performed in triplicate and
repeated at least three times. Data are expressed as mean±
SE. The significance of differences was determined by
One-way ANOVA using SPSS13.0 software (SPSS, Chicago,IL). A value of P< 0.05 was considered to be statistically
significant.
Results
DHA suppresses PA-induced lipids accumulation in HepG2
cells
We first analyzed the lipid accumulation qualitatively
by Oil red O staining. As shown in Figure 1A, HepG2
cells treated for 24 h with PA exhibited significant lipid
droplet accumulation dose-dependently compared with
untreated cells. Preincubation with DHA significantly
prevented 0.4 mM PA-induced lipid deposition and the
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at a dose of 50 μM. DHA alone or vehicle (ethanol) did
not affect basal levels of lipid deposition (data not
shown). To evaluate the effect of PA and DHA on lipids
accumulation quantitatively, we next measured TG con-
centration in cells lysates. Consistently, treatment with
PA resulted in a obvious increase in TG content com-
pared to control cells, which was attenuated signifi-
cantly by pretreatment with 50 μM DHA (Figure 1B).
The lipid deposition and TG content in BSA carrier
control cells were comparable with untreated cells (data
not shown).
DHA attenuates PA-induced inflammatory cytokines in
HepG2 cells
We examined the effects of PA on the productions of IL-
1β, IL-18, TNF-α and MCP-1 in HepG2 cells. Figure 2
showed that PA exposure significantly increased the pro-
ductions of all cytokines in a dose-dependent manner
compared with the control cells. Pretreatment with 50 μM
DHA for 24 h significantly alleviated PA-induced overpro-
duction of all these inflammatory cytokines.
DHA inhibits PA-induced NLRC4 mRNA expression
Since only the processed cytokines are biologically active,
we hypothesized that the inflammasomes which are essen-
tial in regulating the proteolytic maturation of pro-IL-1β
and other proinflammatory cytokines would involved in
PA-induced inflammation. As shown in Figure 3, PA eli-
cited the expression of NLRC4 mRNA in a dose-dependentFigure 2 DHA attenuates PA-induced inflammatory cytokines overpr
cell-free culture supernatants were assayed for IL-1β (A), IL-18 (B), TNF-α (C
of 4 experiments. *P< 0.05, **P< 0.01 compared with untreated cells; #P<manner. DHA pretreatment significantly decreased PA-
induced NLRC4 mRNA expression.
DHA reverses PA-induced lipid accumulation and
inflammation through repressing NLRC4 expression
To test whether NLRC4 might modulate PA-induced stea-
tohepatitis, cells were transfected with NLRC4 siRNA
(NLRC4+/− cells). As shown in Figure 4A, the protein level
of NLRC4 decreased dramatically by 91.2% by the transi-
ent RNA interference technology. Then, NLRC4+/− cells
were exposed to PA with or without DHA preincubation.
Compared to the wild-type cells, the lipid deposition and
TG content were significantly ameliorated in PA-treated
NLRC4+/− cells and were completely abolished by DHA
preincubation (Figure 4B and C). Consistently, DHA al-
most abrogated PA-elicited production of IL-1β, IL-18,
TNF-α and MCP-1 in NLRC4+/− cells (Figure 5). No sig-
nificant difference was observed in cells treated with the
control siRNA compared with untreated cells (Additional
file 1: Figure S1 and Table S1).
DHA inhibits caspase-1 activity and IL-1β maturation
Conversion of the inactive pro-IL-1β to its mature form
IL-1β requires the proteolytic action of IL-1β-converting
enzyme (ICE), which is also termed as caspase-1. The en-
zyme is activated by inflammsomes, such as NLRP3 and
NLRC4 [17]. We tested the effect of DHA on caspase-1 ac-
tivity by an ELISA assay. In the presence of different dose
of PA, caspase-1 activity increased accordingly whereas
partially reversed by DHA preincubation. Compared tooduction in HepG2 cells. Cells were treated accordingly and then
) and MCP-1 (D) by commercial ELISA kits. The data represent a mean
0.01 versus 0.4 mM PA-treated cells.
Figure 3 DHA inhibits PA-induced NLRC4 mRNA expression.
Cells were treated accordingly and then NLRC4 mRNA was
measured by real-time PCR The data are normalized using β-actin as
control and expressed as fold over untreated cells. The experiment
was repeated 4 times. *P< 0.05, **P< 0.01 compared with untreated
cells; #P< 0.01 versus 0.4 mM PA-treated cells.
Figure 4 DHA reverses PA-induced lipid accumulation through
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to a more depressed caspase-1 activity in each experimen-
tal treatment. Furthermore, DHA preincubation completely
reversed PA-induced caspase-1 activation in NLRC4+/−
HepG2 cells (Figure 6A).
To determine the effect of DHA on IL-1β maturation,
we measured the procaspase-1 and pro-IL-1β processing
by western blotting assay. As presented in Figure 6B, PA
elicited caspase-1 and IL-1β release dose-dependently
compared with control cells. DHA reduced PA-induced
procaspase-1 and pro-IL-1β processing significantly. NLRC4
siRNA repressed both caspase-1 and IL-1β release induced
by 0.4 mM PA, and these events were potentiated by the
preincubation of DHA.repressing NLRC4 expression. (A) Generation of a HepG2 cell
model with specific NLRC4 knockdown (NLRC4+/−). NLRC4 and β-actin
protein levels were evaluated by immunoblotting. (B) Representative
Oil Red O staining of wild-type (WT) and NLRC4+/− HepG2 cells were
treated with different dose of PA with or without DHA preincubation
wild-type (WT) and NLRC4+/− cells are shown. Cells were examined by
light microscopy at a magnification of 400×; (C) Intracellular TG
content was measured by an ELISA assay. TG concentration was
normalized by protein content. Data are shown as the mean± S.E.;
n = 4. *P< 0.05, **P< 0.01 compared with untreated cells; #P< 0.01
versus 0.4 mM PA-treated cells.Discussion
NAFLD encompasses four histopathology stages: simple
steatosis, steatosis with inflammation termed as NASH,
cirrhosis and hepatocellular carcinoma [20]. The steato-
sis and inflammation in NASH often result in the follow-
ing more severe liver injuries [21]. Hence, elucidation of
the possible mechanisms responsible for NASH and im-
peding the progress of NASH are of emerging import-
ance. DHA possesses hepatoprotective effects and DHA
supplementation decreases liver fat content in children
with NAFLD [16,22]. In the present study, we reported
that DHA ameliorates PA-induced lipid accumulation,
inflammatory cytokines production in HepG2 cells. Fur-
ther experiments indicated that DHA down regulatesNLRC4 mRNA expression and caspase-1 activity, resulting
in the reduction of IL-1β release. These data suggested
that DHA exerts protective effects on NASH not only at
the 1st hit but also at the 2ed one.
Figure 5 DHA reverses PA-induced inflammation through repressing NLRC4 expression. WT and NLRC4+/− HepG2 cells were treated with
different dose of PA with or without DHA preincubation and then cell-free culture supernatants were assayed for IL-1β (A), IL-18 (B), TNF-α (C)
and MCP-1 (D) by commercial ELISA kits. The data represent a mean of 4 experiments. *P< 0.05, **P< 0.01 compared with untreated cells;
#P< 0.01 versus 0.4 mM PA-treated cells.
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increased lipids deposition and plasma concentrations of
FFAs are elevated in patients with NASH [23,24]. Previous
study has suggested that FFAs induce steatohepatitis by
participating in lipotoxic responses and chronic inflamma-
tory responses [25,26]. It has also been suggested that
saturated FFAs such as laurate and PA increases lipid ac-
cumulation and induces a pro-inflammatory response
[19,27]. In this study, we chose a molar ratio 5:1 of PA to
BSA to mimic the pathophysiological states in which un-
bound FFA concentrations are high [28]. Our data demon-
strates that exposure of HepG2 cells to PA results in lipid
accumulation and the overproduction of inflammatory
cytokines in a dose-dependent manner. This is in agree-
ment with a previous study that the serum concentrations
of FFAs were increased in patients with NAFLD and cor-
related with the development of more severe liver disease
[29]. Importantly, recent evidence showed that saturated
fatty (palmitic) acid activated the inflammasome and trig-
gered release of danger signals from hepatocytes in a cas-
pase-1-dependent manner [30], suggesting that the
activation of inflammasomes also may contribute to the
development of NASH. In the present study, we demon-
strated that PA activated NLRC4 inflammasome function,
indicated by cleavage of procaspase-1 and increased IL-1
production, along with the increased expression of NLRC4
mRNA. This novel observation differs from a previous
report that NLRC4 had no effect on PA-induced IL-1βor IL-18 production in macrophages [17]. The discrep-
ancy may represent cell-specific differences in response
to PA between hepatic cells (HepG2) and macrophages
or pathways by which pro-IL-1β was cleavaged [31].
Interestingly, the knockdown of NLRC4 has not com-
pletely inhibited PA-induced IL-1β production. This ob-
servation complements a previous report that NALP3,
another inflammasome, is involved in PA-induced IL-1β
overproduction in hepatocytes [30].
Our study clearly demonstrates that preincubation
with DHA significantly attenuates the lipid accumulation
and inflammatory cytokines overproduction in cells
exposed to excess PA. It was consistent with a previous
study that DHA alleviates lipid deposition and inflamma-
tion and the supplementation of n-3 PUFAs ameliorates
NAFLD in Japanese men and women [32]. However, the
exact mechanisms of DHA in preventing NASH are not
yet clear. Recent studies demonstrated that DHA inhibits
lipid accumulation by coordinately suppressing lipid syn-
thesis in the liver by impairing the proteolytic release of
SREBP-1c and/or by suppressing SREBP-1c gene expres-
sion and upregulating fatty acid oxidation by serving as
an in vivo activator of peroxisome proliferator-activated
receptor alpha (PPAR-α) [33]. DHA was also found to
exert anti-inflammatory effects by decreasing the pro-
duction of inflammatory eicosanoids [34], reactive oxy-
gen species production [35] and the expression of
adhesion molecules [36,37] or giving rise to a family of
Figure 6 DHA inhibits caspase-1 activity and IL-1β maturation.
WT and NLRC4+/− HepG2 cells were treated with different dose of
PA with or without DHA preincubation and cells were homogenized
in lysis buffer. (A) Caspase-1 activity was determined using
colorimetric assay based on the cleavage of substrate Ac-YVAD-pNA.
The results were expressed as fold over untreated WT cells. *P< 0.05,
**P< 0.01 compared with untreated cells; #P< 0.01 versus 0.4 mM
PA-treated cells. (B) Immunoblot analysis showing caspase-1
cleavage and active IL-1β accumulation. This gel is the representative
image of three independent experiments (upper panel). Quantified
data of protein levels indicates in lower panel. The values of density
of proteins were all justified with β-actin. The relative density ratios
of untreated WT cells were set at a value of 1.0. The values represent
the mean± S.E (*P< 0.05, **P< 0.01 compared with WT cells treated
with 0.4 mm PA for the ratio of caspase-1/procaspase-1; #P< 0.01
versus 0.4 mM PA-treated WT cells for the ratio of IL-1β/pro-IL-1β).
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data suggested that DHA preincubation inhibited PA-
induced NLRC4 inflammasome activation and decreased
the cleavage of procaspase-1 and IL-1 production. Further,
knockdown of NLRC4 significantly inhibited PA-induced
lipid accumulation and almost completely abolished that
in the presence of DHA. To our best knowledge, we
show here for the first time that DHA ameliorates
NASH through suppressing the NLRC4 inflammasome
activation.
Our current study shows that PA triggered caspase-1
activity in a dose-dependent manner whereas DHA
inhibited PA-induced caspase-1 activation, leading to the
decreased cleavage of pro-IL-1β and IL-1β production.
IL-1β has been implicated in the pathogenesis of steato-
hepatitis [39]. Unlike other secreted proteins, IL-1β is
synthesized as a precursor protein pro-IL-1β, whose
multiple extracellular activities in response to various
proinflammatory stimuli are attributed to receptor bind-
ing of IL-1β itself [31,40]. It is generally accepted that
cleavage of pro-IL-1β is mediated by inflammasomes
[41] and conversion of the inactive pro-IL-1β to IL-1β
requires the proteolytic action of caspase-1 [42]. It was
suggested that the specific inhibition of caspase-1 by the
caspase inhibitor blocked the maturation of IL-1β [43]
and no significant IL-1β produced in PA-treated macro-
phages derived from caspase-1−/− mice [17]. We showed
an inhibitory effect of DHA on caspase-1 activity and
IL-1β maturation in HepG2 cells, an effect which, to our
best knowledge, has not been reported previously.
Inflammation is a response to lipid accumulation and
can accelerate the injury. Treatment of mice with IL-1β
decreased fatty acid metabolism, resulting in hepatic trigly-
ceride storage [44]. In the present study, we found that
knockdown of NLRC4 inhibited PA-induced inflammation,
thereby further attenuating lipid accumulation in cells.
This is agreement with previous studies that IL-1β stimula-
tion exacerbates lipid accumulation in hepatic cells and
fatty livers of apolipoprotein E knockout mice [45] and
enhanced liver injury induced by inflammatory stress was
observed in NASH [46]. Thus, exposure of DHA is effect-
ive for preventing and reversing lipid accumulation and
the inflammatory response which may accelerate the lipid
metabolism disorder and/or more severe liver injuries.
In summary, our present findings clearly show that PA
triggers lipid accumulation and inflammatory cytokines
overgeneration in HepG2 cells, which is ameliorated by
DHA through attenuating NLRC4 inflammasome activa-
tion, caspase-1 activation and IL-1β cleavage. Taken to-
gether, these data suggests that DHA may server as a
potential nutrient antagonist to NLRC4 and our findings
offer new insights into the potential mechanisms of action
of DHA in mediating the beneficial hepatoprotective
effects in NASH.
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Additional file 1: Figure S1. Representative Oil Red O staining of
cells with different treatments is shown. Cells were transiently
transfected with 20 pmoL control siRNA or NLRC4 siRNA for 48 h and
examined by light microscopy at a magnification of 400×. The images are
representative of typical staining. Table S1. Effects of siRNA
transfection on the production of cytokines (mean ± SE; pg/mL) in
HepG2 cells. Cells were transiently transfected with 20 pmoL control
siRNA or NLRC4 siRNA for 48 h. Then the cell-free culture supernatants
were centrifuged at 10,000 g for 10 min at 4°C and the supernatants
were stored at -20°C before assaying IL-1β, IL-18, TNF-α and MCP-1 by
commercial ELISA kits. The data represent a mean of 4 experiments.
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